Articles with public access mandates - Kwong-Kwok WongLearn more
Not available anywhere: 4
Low-grade serous ovarian cancer: state of the science
B Slomovitz, C Gourley, MS Carey, A Malpica, IM Shih, D Huntsman, ...
Gynecologic oncology 156 (3), 715-725, 2020
Mandates: Cancer Research UK
Low-grade serous carcinoma: new concepts and emerging therapies
I Romero, CC Sun, KK Wong, RC Bast Jr, DM Gershenson
Gynecologic oncology 130 (3), 660-666, 2013
Mandates: US National Institutes of Health
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance
LP Cobb, CC Sun, R Iyer, AM Nick, ND Fleming, SN Westin, AK Sood, ...
Gynecologic oncology 158 (3), 653-658, 2020
Mandates: US National Institutes of Health
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes
DM Gershenson, CC Sun, SN Westin, M Eyada, LP Cobb, LC Nathan, ...
Gynecologic oncology 165 (3), 560-567, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Available somewhere: 52
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
CL Au Yeung, NN Co, T Tsuruga, TL Yeung, SY Kwan, CS Leung, Y Li, ...
Nature communications 7 (1), 11150, 2016
Mandates: US National Institutes of Health
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment
TL Yeung, CS Leung, KK Wong, G Samimi, MS Thompson, J Liu, TM Zaid, ...
Cancer research 73 (16), 5016-5028, 2013
Mandates: US National Institutes of Health
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2
SC Mok, T Bonome, V Vathipadiekal, A Bell, ME Johnson, DC Park, ...
Cancer cell 16 (6), 521-532, 2009
Mandates: US National Institutes of Health
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
KK Wong, YTM Tsang, MT Deavers, SC Mok, Z Zu, C Sun, A Malpica, ...
The American journal of pathology 177 (4), 1611-1617, 2010
Mandates: US National Institutes of Health
MEK inhibitor resistance mechanisms and recent developments in combination trials
E Kun, YTM Tsang, CW Ng, DM Gershenson, KK Wong
Cancer treatment reviews 92, 102137, 2021
Mandates: US Department of Defense
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low‐grade serous carcinoma
YT Tsang, MT Deavers, CC Sun, SY Kwan, E Kuo, A Malpica, SC Mok, ...
The Journal of pathology 231 (4), 449-456, 2013
Mandates: US National Institutes of Health
Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare …
DM Gershenson, DC Bodurka, KH Lu, LC Nathan, L Milojevic, KK Wong, ...
Journal of Clinical Oncology 33 (24), 2675-2682, 2015
Mandates: US National Institutes of Health
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
CS Leung, TL Yeung, KP Yip, KK Wong, SY Ho, LS Mangala, AK Sood, ...
The Journal of clinical investigation 128 (2), 589-606, 2018
Mandates: US Department of Defense, US National Institutes of Health
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential
CS Leung, TL Yeung, KP Yip, S Pradeep, L Balasubramanian, J Liu, ...
Nature communications 5 (1), 5092, 2014
Mandates: US National Institutes of Health
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
CS Tung, SC Mok, Y Tsang, Z Zu, H Song, J Liu, MT Deavers, A Malpica, ...
Modern Pathology 22 (9), 1243-1250, 2009
Mandates: US National Institutes of Health
Insulin-like growth factor: current concepts and new developments in cancer therapy
E R King, KK Wong
Recent patents on anti-cancer drug discovery 7 (1), 14-30, 2012
Mandates: US National Institutes of Health
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer
ER King, CS Tung, YTM Tsang, Z Zu, GTM Lok, MT Deavers, A Malpica, ...
The American journal of surgical pathology 35 (6), 904-912, 2011
Mandates: US National Institutes of Health
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer
TM Zaid, TL Yeung, MS Thompson, CS Leung, T Harding, NN Co, ...
Clinical Cancer Research 19 (4), 809-820, 2013
Mandates: US National Institutes of Health
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells
TL Yeung, CS Leung, KK Wong, A Gutierrez-Hartmann, J Kwong, ...
Oncotarget 8 (10), 16951, 2017
Mandates: US National Institutes of Health
Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways
AM Adesina, D Lopez-Terrada, KK Wong, P Gunaratne, Y Nguyen, ...
Human pathology 40 (6), 843-853, 2009
Mandates: US National Institutes of Health
Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer
DC Park, SG Yeo, MR Wilson, JJ Yerbury, J Kwong, WR Welch, YK Choi, ...
Neoplasia 10 (9), 964-IN7, 2008
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program